Clinical Issues in Severe Asthma: Consensus and Controversies on the Road to Precision Medicine
This CME-accredited Clinical IssuesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the management of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate a series of topics related to the evaluation and long-term treatment of various severe asthma phenotypes. Activity topics include classification of severe asthma, disease biomarkers, comorbidity management, and current and emerging targeted biologic therapies. The goal is to provide clinician learners with the latest evidence and a fresh perspective on evolving management paradigms for severe asthma.
The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicicians involved in the management of patients with severe asthma.
Upon completion of this activity, participants will be better able to do the following:
- Describe pathophysiology of severe asthma with a focus on helper T cell type 2 (Th2)–mediated processes, biomarkers of disease phenotypes, and treatment targets
- Evaluate patients with severe asthma for symptom severity, exacerbation history, comorbidities, disease phenotypes, and prior treatment responses
- Discuss the clinical profiles of cytokine-targeting biologic medications for the treatment of severe asthma
- Individualize therapeutic regimens for severe asthma based on identified disease phenotypes, ongoing evaluations of symptoms, exacerbation risks, and comorbid conditions
Eugene R. Bleecker, MD
Reynold A. Panettieri, Jr., MD
Sally E. Wenzel, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Eugene R. Bleecker, MD
Consultant/Advisor: AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Knopp Biosciences LLC; MedImmune; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLC.
Grant/Research Support: AstraZeneca; Boehringer Ingelheim GmbH, Genentech, Inc.; GlaxoSmithKline plc; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.
|Reynold A. Panettieri, Jr., MD|
Consultant/Advisor: AstraZeneca; MedImmune; Novartis Pharmaceuticals Corporation.
Grant/Research Support: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; OncoArendi Therapeutics; RFIM; Theratrophix, LLC.; Vertex Pharmaceuticals Incorporated.
Speakers' Bureau: Boston Scientific Corporation; Teva Pharmaceutical Industries Ltd.
|Sally E. Wenzel, MD|
Consultant/Advisor: AstraZeneca; Boehringer Ingelheim GmbH; Genentech, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC.Grant/Research Support: AstraZeneca; Boehringer Ingelheim GmbH.; Genentech, Inc.; GlaxoSmithKline plc; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC.
Non-faculty: Rose O’Connor, PhD, CHCP; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician